Pliant Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLRX research report →
Range $2 – $48
Price Chart
About the company
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials.
- CEO
- Bernard Coulie
- IPO
- 2020
- Employees
- 49
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on PLRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $63.78M
- P/E
- -0.69
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.43
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.22%
- ROIC
- -55.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,696,000+0.0%
- Op Income
- $-150,073,000
- Net Income
- $-149,344,000+29.0%
- EPS
- $-2.43+30.0%
- OCF Growth
- +17.5%
- FCF Growth
- +19.2%
- 52W High
- $1.95
- 52W Low
- $1.01
- 50D MA
- $1.10
- 200D MA
- $1.19
- Beta
- 1.28
- RSI (14)
- 37
- Avg Volume
- 488.36K
No earnings-call transcripts are available for PLRX yet.
- Free Float
- 92.6%
- Shares Outstanding
- 61.92M
- Float Shares
- 57.32M
of shares held by institutions
94 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Tang Capital Management LLC | 6.14M | ▼ 1.87K |
| Adar1 Capital Management, LLC | 5.51M | ▲ 2.92M |
| Vanguard Group Inc | 2.82M | ▲ 42.30K |
| Vanguard Capital Management LLC | 2.44M | ▲ 97.25K |
| Acadian Asset Management LLC | 2.42M | 0 |
| Two Sigma Investments, LP | 2.26M | ▲ 9.69K |
| Citadel Advisors LLC | 2.14M | ▼ 1.08M |
| Renaissance Technologies LLC | 2.05M | ▲ 197.03K |
| Monaco Asset Management Sam | 1.94M | 0 |
| Lynx1 Capital Management LP | 1.80M | ▲ 1.80M |
| Bml Capital Management, LLC | 1.55M | 0 |
| Prosight Management, LP | 1.37M | ▼ 297.37K |
Held by 35 ETFs
Biggest fund positions in PLRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Raben David | other | 575,000 |
| Sep 30, 26 | Raben David | other | 0 |
| Jul 9, 26 | Iannone Robert | other | 0 |
| Jul 9, 26 | Iannone Robert | other | 60,000 |
| Jul 9, 26 | Borellini Flavia | other | 0 |
| Jul 9, 26 | Borellini Flavia | other | 60,000 |
| Jun 11, 26 | CROWELL GAYLE A | other | 70,000 |
| Jun 11, 26 | MCCOURT Thomas A | other | 70,000 |
| Jun 11, 26 | Krognes Steve E. | other | 70,000 |
| Jun 11, 26 | Curnutte John T | other | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLRX coverage
Recent articles, reports, and earnings notes.
No research on PLRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLRX report →Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
globenewswire.com · Sep 30
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
defenseworld.net · Sep 11
Connor Clark & Lunn Investment Management Ltd. Makes New $611,000 Investment in Pliant Therapeutics, Inc. $PLRX
defenseworld.net · Sep 1
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
globenewswire.com · Aug 18
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 11
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.
globenewswire.com · Jul 13
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
seekingalpha.com · May 22
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
globenewswire.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.